This is a mechanistic review integrating evidence from pulmonary medicine, coagulation biology, stroke pathology, and neurodegeneration research. It proposes a lung-to-brain immunothrombosis framework, suggesting convergent immune programs across pulmonary diseases couple inflammation to coagulation. The hypothesis states dysregulated thromboinflammation drives endotheliopathy, platelet–leukocyte cooperation, NET formation, complement activation, tissue factor–thrombin signaling, and fibrinolytic shutdown, culminating in microvascular thrombosis and organ injury. The authors propose these same modules may reshape stroke biology and potentially couple vascular dysfunction to cognitive decline and neurodegenerative trajectories.
No specific study population, sample size, setting, intervention, comparator, or primary outcomes are reported. The review does not present quantitative results, effect sizes, or statistical measures. Safety, tolerability, and adverse event data are not reported.
Key limitations stem from the nature of the work: it is explicitly presented as a mechanistic integration hypothesis intended to identify shared therapeutic nodes and guide cross-disciplinary validation, rather than a demonstrated biological sequence. The authors caution against overstating association versus causation and hypothesis versus demonstrated sequence. Funding and conflicts of interest are not reported.
Practice relevance is not reported. For clinicians, this review serves as a conceptual framework highlighting potential shared biological pathways between pulmonary disease, stroke, and neurodegeneration. It may inform future research questions and therapeutic target identification but does not provide evidence to change current clinical practice.
Researchers examined existing evidence from different medical fields to understand how lung problems might connect to brain issues. They looked at studies about breathing conditions, blood clotting, stroke, and brain health. The goal was to see if there might be shared biological pathways linking these different areas of medicine.
The review suggests that inflammation in the lungs might activate the body's clotting system in a specific way. This process, called immunothrombosis, could potentially travel from the lungs to affect blood vessels in the brain. The researchers propose this might increase stroke risk and possibly influence long-term brain health in some people.
It's important to understand this is currently a hypothesis—a scientific idea that needs testing. The researchers have connected dots from different research areas, but this pathway hasn't been proven to actually work this way in people. No new treatments or prevention strategies come from this review alone.
Readers should know this represents early-stage thinking about how different health problems might be connected. While interesting for researchers, it doesn't change current medical advice for lung conditions, stroke prevention, or brain health. More studies are needed to see if this proposed connection actually exists.
What this means for you: Early research suggests a possible link between lung inflammation and brain health, but this connection needs much more study.
View Original Abstract ↓
Pulmonary diseases increasingly reshape vascular biology and coagulation beyond the lung. Across acute infections and acute respiratory distress syndrome (ARDS), chronic airway inflammation (e.g., COPD), sleep-disordered breathing, fibrotic interstitial lung disease, and particulate air pollution, convergent immune programs couple inflammation to coagulation through immunothrombosis. Physiologic immunothrombosis can confine pathogens within the microvasculature, but dysregulated thromboinflammation drives endotheliopathy, platelet–leukocyte cooperation, neutrophil extracellular trap (NET) formation, complement activation, tissue factor–thrombin signaling, and fibrinolytic shutdown, culminating in microvascular thrombosis and organ injury. Emerging clinical and translational data suggest that these same modules may reshape stroke biology: NET-rich thrombi are linked to recanalization failure and thrombolysis resistance; systemic endotheliopathy can destabilize the blood–brain barrier and promote no-reflow; and complement–coagulation crosstalk amplifies neurovascular injury. Beyond acute events, chronic microvascular thrombosis and blood–brain barrier leakage allow fibrin(ogen) and coagulation proteases to signal through microglia and protease-activated receptors, potentially coupling vascular dysfunction to cognitive decline and neurodegenerative trajectories. Here we integrate convergent but independently derived evidence from pulmonary medicine, coagulation biology, stroke pathology, and neurodegeneration research into a lung-to-brain immunothrombosis framework. Because these evidence streams have developed largely in parallel, this synthesis represents a mechanistic integration hypothesis—intended to identify shared therapeutic nodes and guide cross-disciplinary validation—rather than a demonstrated biological sequence. We outline biomarker-guided strategies that pair conventional antithrombotics with targeted anti-thromboinflammatory approaches (NET-, complement-, and endothelial/adhesion-directed) while managing bleeding risk.
